Skip to content

Research on dose-response relationship of Remazolam toluenesulfonic acid for induction of general anesthesia

Research on dose-response relationship of Remazolam toluenesulfonic acid for induction of general anesthesia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039881
Enrollment
Unknown
Registered
2020-11-13
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Induction of general anesthesia

Interventions

Optimal drug concentration group:Different concentrations of remazolam toluenesulfonic acid were applied to explore the drug concentration needed to achieve the depth of anesthesia.
Remazolam toluenesulfonic acid group:The best drug concentration of toluene sulfonic acid was applied during induction of general anesthesia, and the peak time of drug effect was observed
The propofol group:Propofol 2.5mg/kg was routinely induced by general anesthesia

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60, regardless of gender; 2. 19kg/m2 <= BMI <= 30kg/m2; 3. ASAI-II;General anesthesia within 2 hours(Endotracheal intubation is to be performed); 4. Clearly understand and voluntarily participate in the study, and the informed consent shall be signed by himself or his legal guardian.

Exclusion criteria

Exclusion criteria: 1. Known allergy or contraindication to benzodiazepines, flumazine, anesthetics; 2. Patients with a history of severe liver and kidney dysfunction, myasthenia gravis, and other abnormal laboratory tests and tests were considered clinically significant; 3. Those who have taken benzodiazepines for a long time and have used sedation or opioid analgesics in the past 5 days; 4. A pregnant or lactating woman; 5. Mallampati Score is assessed as 4 points; 6. The investigator considers the subjects to have any factors that would make them unfit to participate in the study.

Design outcomes

Primary

MeasureTime frame
Entropy index;Drug effect peak time T;

Countries

China

Contacts

Public ContactWenyuan Wang

Zhejiang Provincial People's Hospital

Neuro-anesth@hotmail.com+86 13588083716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026